CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 24 enrolled
Drug / intervention
Salbutamol +2 moredrug
Likely dose
Salbutamol 90 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03556683
NCT03556683N/ACompleted
CompareCT.gov

Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics

University of North Carolina, Chapel Hill·interventional·Posted Jun 14, 2018·Updated Aug 5, 2025

In Brief

A clinical study evaluating 3% Hypertonic Saline, 7% Hypertonic Saline, and 1 other intervention for Moderate to Severe Asthma. Completed, enrolled 24 participants across 1 site.

Detailed Summary

Purpose: To determine if inhaled hypertonic saline (HS) accelerates airway mucociliary clearance (MCC) in well-controlled moderate to severe asthmatics.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate to Severe Asthma
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJun 14, 2018
Enrollment StartOct 1, 2018
Primary CompletionJun 6, 2024
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 8.0 years ago

Interventions

3% Hypertonic Salinedevice

4 mL of 3% hypertonic saline

7% Hypertonic Salinedevice

4 mL of 7% hypertonic saline

Salbutamoldrug

4 puffs (90 mcg/actuation)